• 1
    Vergilio JA, Bagg A. Myelodysplastic syndromes. Contemporary biologic concepts and emerging diagnostic approaches. Am J Clin Pathol 2003;119(Suppl):S5877.
  • 2
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):20792088.
  • 3
    Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;99(1):391392.
  • 4
    Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102(1):394403.
  • 5
    Del Canizo MC, Fernandez ME, Lopez A, et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003;88(4):402407.
  • 6
    Maynadie M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100(7):23492356.
  • 7
    Cherian S, Moore JS, Bantly A, et al. The peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B: Clin Cytometry 2005;64B(1):917.
  • 8
    Jaffe ES, Harris N, Stein H, Vardiman JW (editors). World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon:IARC Press;2001.
  • 9
    Mitelman F (editor). ISCN 1995: An international system for human cytogenetic nomenclature. Basel:Karger; 1995.